Larvol Delta

abrilumab (AMG 181) - Amgen

AZ: Investor Day (AstraZeneca) - Mar 21, 2013 - Anticipated data from P2 trial for Crohn's disease in 2014; Anticipated data from P2 trial for ulcerative colitis in 2014
Anticipated P2 data • Inflammatory Bowel Disease

http://www.astrazeneca.com/Media/Events-calendar

Mar 21, 2013